Anti-CD40 agonist antibodies: preclinical and clinical experience.
about
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesMonoclonal antibodies for the treatment of cancerA current perspective on applications of macrocyclic-peptide-based high-affinity ligandsMechanisms of action of therapeutic antibodies for cancerSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesInhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Agonistic anti-CD40 induces thyrocyte proliferation and promotes thyroid autoimmunity by increasing CD40 expression on thyroid epithelial cells.Twelve immunotherapy drugs that could cure cancers.Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.Modulation of tumor immunity by therapeutic monoclonal antibodies.T-cell-independent antitumor effects of CD40 ligation.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas.Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.
P2860
Q26781215-A2301A20-3A9C-4C4A-8542-53436A27E914Q27025966-4D455A4D-61C3-4E09-AE3F-5D897793093DQ28072407-91333A68-C0CE-4897-B899-962E7A5266C1Q28385366-CB751DD4-0F73-47AF-8D42-9FEF17C703CDQ33895804-EBE85E7B-1BB8-4F46-9BE1-2A3A8B2F095AQ33903025-8192D467-8F36-4F80-91ED-09CC8928E7CFQ34111693-4AD4F35D-F707-4BC5-99A7-1908CE243AD4Q34405616-33698EC9-8534-4C06-BEAC-7DADEA876183Q34661963-1EE4C841-A3DC-4D1A-BDC8-175C0A739581Q36465489-2217A349-713F-4886-B568-ABF9FDDB1B0EQ36754417-86B7F20F-8416-476E-8896-387F2E4710B9Q37118201-F4525733-8BDC-4DB9-B8C9-3CF0434234C1Q37273700-21A60B9B-A653-4BC1-8508-F69680CD137FQ37832438-86B731DA-235C-4FC1-888D-8787535721A9Q38026925-755ADBC6-7C36-4C1A-A9CB-A61BEE76834EQ38108836-9C2BF83A-A37C-477B-9254-F710BD15DE97Q38779032-AAFE8BAD-A99A-4F8B-B8FC-192FBEE229FBQ39155565-947CCA2C-EE2C-4B15-93C1-00F2A610D639Q40560816-2E3B2DB2-1C58-42AC-9AF9-DF8B99B79D2BQ42280832-B1DA1D02-F331-4930-B6DA-7CD8AC52202DQ42506621-DB75EBA6-022B-495A-8E46-C6829B68171DQ47094002-72E0D90D-1041-482A-A71E-2393B7A1EB28
P2860
Anti-CD40 agonist antibodies: preclinical and clinical experience.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@en
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@nl
type
label
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@en
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@nl
prefLabel
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@en
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@nl
P2860
P1476
Anti-CD40 agonist antibodies: preclinical and clinical experience.
@en
P2093
Magi Khalil
Robert H Vonderheide
P2860
P356
10.1016/J.UCT.2007.06.001
P577
2007-06-01T00:00:00Z